Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
578.56B
Market cap578.56B
Price-Earnings ratio
27.56
Price-Earnings ratio27.56
Dividend yield
2.20%
Dividend yield2.20%
Average volume
8.11M
Average volume8.11M
High today
$240.51
High today$240.51
Low today
$237.52
Low today$237.52
Open price
$240.01
Open price$240.01
Volume
1.83M
Volume1.83M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $240.35. The company's market cap stands at 578.56B, with a P/E ratio of 27.56 and a dividend yield of 2.2%.

On 2026-06-12, Johnson & Johnson(JNJ) stock traded between a low of $237.52 and a high of $240.51. Shares are currently priced at $240.35, which is +1.2% above the low and -0.1% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 1.83M, against a daily average of 8.11M.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

JNJ News

Simply Wall St 26m
Johnson & Johnson’s TECNIS PureSee Rollout And What It Means For JNJ Stock

Johnson & Johnson (NYSE:JNJ) has expanded U.S. availability of its TECNIS PureSee intraocular lens, described as the first FDA approved extended depth of focus...

Johnson & Johnson’s TECNIS PureSee Rollout And What It Means For JNJ Stock
24/7 Wall St. 3h
The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar

The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar By Drew Wood Published Jun 12, 8:18AM EDT Quick Read A $...

The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar
New York Times 6h
What we saw from Kyler Murray and J.J. McCarthy (and other positions) at Vikings minicamp - The New York Times

...

What we saw from Kyler Murray and J.J. McCarthy (and other positions) at Vikings minicamp - The New York Times

Analyst ratings

68%

of 25 ratings
Buy
68%
Hold
28%
Sell
4%

More JNJ News

Benzinga 23h
Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder

The rare blood disorder occurs when the immune system mistakenly produces IgG antibodies that attack and destroy healthy red blood cells at normal body temperat...

Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder
TipRanks 1d
Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Johnson & Johnson is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses. TECNIS PureSee IOL is an extended depth...

24/7 Wall St. 1d
A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell

A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell By Drew Wood Published Jun 11, 5:57AM EDT Quick Read...

A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell
TipRanks 1d
Johnson & Johnson presents first results from ENERGY study

Johnson & Johnson presented the first results from the Phase 2/3 ENERGY study showing that Imaavy produced a statistically significant durable hemoglobin, or Hg...

24/7 Wall St. 2d
The Portfolio That Gets You a Waterfront Condo in Miami Beach

The Portfolio That Gets You a Waterfront Condo in Miami Beach By Drew Wood Published Jun 10, 11:24AM EDT Quick Read Generating $120,000 in annual dividends re...

The Portfolio That Gets You a Waterfront Condo in Miami Beach
24/7 Wall St. 2d
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond

Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond By Alex Sirois Published Jun 10, 11:20AM EDT Quick Read JNJ holds an AA...

Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
24/7 Wall St. 2d
The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep By Drew Wood Published Jun 10, 7:04AM EDT Quick Read A $1M portfolio in dividend gro...

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.